Publicaciones (30) Publicaciones de Purificación Martínez del Prado

2024

  1. Thrombosis in breast cancer patients on cyclin-dependent kinase inhibitors: Survival impact and predictive factors - A study by the cancer and thrombosis group of the spanish society of medical oncology (SEOM)

    European Journal of Internal Medicine

2023

  1. Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry

    Breast Cancer Research and Treatment, Vol. 201, Núm. 2, pp. 151-159

2022

  1. Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial

    Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661

  2. Erratum: TEMPORARY REMOVAL: PO-14: Real-world data: incidence of venous thromboembolism recurrence and bleeding among cancer patients (Thrombosis research PII: S0049-3848(22)00202-X)

    Thrombosis research

  3. Incidence, risk factors, and evolution of venous thromboembolic events in patients diagnosed with pancreatic carcinoma and treated with chemotherapy on an outpatient basis

    European Journal of Internal Medicine, Vol. 105, pp. 30-37

2021

  1. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

    The Lancet Oncology, Vol. 22, Núm. 4, pp. 463-475

  2. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

    Annals of Oncology, Vol. 32, Núm. 10, pp. 1245-1255

  3. Incidence and clinical pattern of contralateral synchronous and metachronous germ cell testicular cancer

    Urologic Oncology: Seminars and Original Investigations, Vol. 39, Núm. 2, pp. 135.e17-135.e23

  4. The prognostic value of respiratory symptoms and performance status in ambulatory cancer patients and unsuspected pulmonary embolism; analysis of an international, prospective, observational cohort study

    Journal of Thrombosis and Haemostasis, Vol. 19, Núm. 11, pp. 2791-2800

2019

  1. Biological and prognostic differences between symptomatic colorectal carcinomas and those detected by screening

    European Journal of Surgical Oncology, Vol. 45, Núm. 10, pp. 1876-1881

  2. Impact of an osteoporosis specialized unit on bone health in breast cancer survivals treated with aromatase inhibitors

    Reumatologia Clinica, Vol. 15, Núm. 4, pp. 211-217

2018

  1. Cost-effectiveness analysis of laparoscopic versus open surgery in colon cancer

    Surgical Endoscopy, Vol. 32, Núm. 12, pp. 4912-4922

  2. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)

    Oncologist, Vol. 23, Núm. 4, pp. 422-432

  3. Outcomes of open versus laparoscopic surgery in patients with colon cancer

    European Journal of Surgical Oncology, Vol. 44, Núm. 9, pp. 1344-1353

2017

  1. Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM “El Álamo III” retrospective study

    PLoS ONE, Vol. 12, Núm. 10

  2. Functional proteomics outlines the complexity of breast cancer molecular subtypes

    Scientific Reports, Vol. 7, Núm. 1

  3. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 18, Núm. 12, pp. 1688-1700

2016

  1. Albumin-Bound (NAB) Paclitaxel, Abraxane®

    The Easy Book of Cancer Pharmacology (Nova Science Publishers, Inc.), pp. 7-17

  2. Docetaxel.Taxotere®

    The Easy Book of Cancer Pharmacology (Nova Science Publishers, Inc.), pp. 139-145

  3. Gemcitabine. Gemzar®

    The Easy Book of Cancer Pharmacology (Nova Science Publishers, Inc.), pp. 197-205